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ABSTRACT
Objectives: The aim of our study is to perform the clinical, functional and ultrasonographic (US) follow-up of the early and very early RA patient who 
are naive among the disease modifying antirheumatic drugs (DMARDs) for 18 months and evaluate the relationship of these parameters with the 
radiological final state.
Material and Methods: This prospective study included 48 early RA (15 very early RA) patients. Gray scale US (GSUS), Power Doppler US (PDUS) 
examinations, Disease Activity Score 28 (DAS 28), Health Assessment Questionnaire (HAQ), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein 
(CRP) were evaluated repeatedly at each visit (baseline, 1, 3, 6, 9, 12, 18 months). Hand, wrist, elbow, shoulder, knee joints and hand, wrist tendon 
structures were evaluated via GSUS and PDUS.
Results: During the follow-up period of the patients, the ESR and CRP levels started to decrease statistically significantly from the 1st month (p=0.006). 
Statistically significant improvement in HAQ, DAS 28 scores, total GSUS synovitis scores, total PDUS tenosynovitis scores, total GSUS tenosynovitis 
scores, total PDUS tenosynovitis scores started at 3th months (p=0.007, p=0.003, p=0.001, p=0.009, p=0.002, p=0.004 respectively). In follow-up of very 
early RA patients; laboratory, US findings were similar to early RA patients. In multiple linear regression analysis, only the GSUS and PDUS scores at 0 
and 1, could have an effect on the radiographic progression scores (ß=0.417, p=0011, ß=0.549, p=0.028, ß=0.476, p=0015; ß=0.358, p=0.017, respectively).
Conclusions: Radiographic damage progresses at the similar severity in early and very early RA patients. The most important factor affecting the 
radiographic damage progression is the severity of US synovitis at the baseline and in the 1st month, independently of the disease activity.
Keywords: Inflammation, rheumatoid arthritis, synovitis, ultrasonography
ÖZ
Erken romatoid artrit hastalarının klinik ve ultrasonografik bulguları: 18 aylık takip çalışması
Amaç: Çalışmamızın amacı erken ve çok erken tanı konulmuş hastalık modifiye edici ajanlardan naif olan romatoid artrit (RA) hasta grubunun, 18 ay 
boyunca klinik, fonksiyonel, ultrasonografi (US) takibini yapmak ve bu parametrelerin radyolojik son durum ile ilişkilerini değerlendirmektir.
Gereç ve Yöntemler: Çalışmamıza 48 erken RA (15’i çok erken RA) tanılı hasta dahil edildi. Gri skala US (GSUS) ve Power Doppler US (PDUS) 
muayenesi, 28 eklem hastalık aktivite skoru (DAS28), sağlık değerlendirme anketi (HAQ), eritrosit sedimantasyon hızı (ESH), C reaktif protein (CRP) 
düzeyleri başlangıçta, 1, 3, 6, 9, 12, 18 aylarda tüm hastalarda yapıldı. Elbilek, metokarpofalangeal, proksimal interfalangeal, dirsek, omuz ve diz 
eklemleri ve elbilek çevresi tendon yapıları GSUS ve PDUS ile değerlendirildi.
Bulgular: Hastaların takibinde ESH, CRP seviyelerinde 1. aydan itibaren istatistiksel olarak anlamlı bir şekilde azalma başladı (p=0.006). HAQ, DAS 
28 skorları, toplam GSUS sinovit skorları, toplam PDUS tenosinovit skorları, toplam GSUS tenosinovit skorları, toplam PDUS tenosinovit skorlarında 
istatistiksel olarak anlamlı düzelme ise ancak 3. ayda başlamaktadır (sırasıyla; p=0.007, p=0.003, p=0.001, p=0.009, p=0.002, p=0.004). Çok erken RA 
hastalarının izleminde laboratuar, US bulguları erken RA hastalarına benzer bulundu. Çoklu lineer regresyon analizinde, sadece 0 ve 1. Aydaki toplam 
GSUS ve PDUS skorları radyografik ilerleme skorları üzerine etkisini devam ettirebilmiştir (sırasıyla, ß=0.417, p=0011; ß=0.549, p=0.028; ß=0.476, 
p=0015; ß=0.358, p=0.017).
Sonuç: Radyografik hasarda ilerleme erken ve çok erken RA hastalarında benzer şiddette olmaktadır. Radyografik hasarın ilerlemesini etkileyen en 
önemli faktör, hastalık aktivitesinden bağımsız olarak, başlangıçtaki ve 1. aydaki US sinovitinin şiddetidir.
Anahtar kelimeler: İnflamasyon, romatoid artrit, sinovit, ultrasonografi
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 INTRODUCTION
 The evaluation of the disease activity in rheumatoid 
arthritis (RA) is quite important in determining the treatment 
strategy, prognosis assay, and final state prediction. Clinical 
examination, laboratory, and sensitive radiological methods 
are used in determining the disease activity.  Nowadays, the 
treatment goals in RA are low disease activity and clinical 
remission. The advancement in the imaging technology 
brought forward evaluating with sensitive radiological 
methods such as ultrasonography (US) and magnetic 
resonance (MR). Hence, it has been shown radiologically 
that erosions develop in the following years even in the 
patients who are clinically in remission nowadays (1,2). 
These observations change the treatment goals in RA to the 
radiological remission along with the clinical remission.
 US is a method which is quite practical and repeatable to 
be applied clinically in RA. Grey-scale US (GSUS) detects 
synovitis and differently from GSUS, Power Doppler (PD) 
signal is a quite effective method of distinguishing the early 
and active disease. It was shown that PDUS distinguishes 
the acute and chronic disease more precisely in synovium 
(3,4). In cross-sectional studies, subclinical synovitis in US 
in the patients who were clinically in remission was 
elaborated much more (5,6). These are some studies in the 
literature in which joint US was used for the long-term 
follow-up in early RA patients (7,8). While the disease 
follow-up periods were short and the US follow-up intervals 
were long in the studies, the disease groups also consisted 
of rather established RA patients. Thus, evaluating the US 
response to the treatment does not seem sound.
 The purpose of our study is to perform the clinical, 
functional and US follow-up of the early and very early-
diagnosed RA patient group which is naive among the 
disease modifying antirheumatic drugs (DMARDs) for 18 
months and evaluate the relationship of these parameters 
with the radiological final state. 
 MATERIAL AND METHODS
 This prospective study included 48 early RA (15 very 
early RA) patients according to the American College of 
Rheumatology/European League Against Rheumatism 
(ACR/EULAR) RA 2010 classification criteria between 
January 2013 and August 2015. Patients were recruited from 
the rheumatology outpatient clinics at the same center. All 
patients evaluated by ACR/EULAR 2010 RA classification 
criteria feature; (a) joint involvement, (b) rheumatoid factor 
(RF) and anti-citrullinated protein antibody (anti-cyclic 
citrullinated peptide (CCP)) levels, (c) acute phase reactant 
levels, and (d) duration of symptoms, consecutively included 
in the study (9). The early RA term definition based on the 
onset of RA symptoms. The threshold of symptom duration 
is 6 months for early RA and 3rd months for very early RA. 
The study protocol was approved by our local ethics 
committee, and informed consent was obtained from all 
patients. Patients who have any kind of cancer,  or 
hematological abnormality, those who were pregnant or in 
the post-partum period (6 months), and those who had 
previously taken low-dose corticosteroids or synthetic 
DMARDs were excluded.
 Gender, age, DMARD type, body mass index (BMI), the 
number of tender and swollen joints, and the patient’s 
assessment of disease activity (0–10 scale) were recorded. 
Initially, patients received synthetic DMARDs or 
corticosteroids (<10 mg/day). Disease activity was assessed 
by calculating the Disease Activity Score (DAS 28).
 DAS 28 remission criteria, involving C reactive protein 
(CRP), swollen and tender joint counts and patient’s global 
health assessment were used to determine whether the 
disease in remission. A score of DAS28 between 2.6-3.2 
indicates low disease activity, 3.2-5.1 moderate and > 5.1 
high disease activity (10). If the clinical response  was 
inadequate (improvement of the 28-joint disease activity 
score [DAS28] <0.6) at 3rd months, another synthetic or 
biologic DMARD was added to the therapy.
 To evaluate quality of life, the Health Assessment 
Questionnaire (HAQ) disability index (consisting of 20 
questions) was applied (11).
 Laboratory assessment included measurement of 
erythrocyte sedimentation rate (ESR), level of C-reactive 
protein (CRP), rheumatoid factor (RF), and anti-cyclic 
citrullinated peptide (anti-CCP) antibody.
 The ESR was measured immediately after blood 
collection by using a Greiner SRS 20/II instrument (Vacuette 
Greiner, Austria). RF and CRP levels were measured by 
nephelometric methods, using an IMAGE 800 analyzer 
(Beckman Coulter Inc., USA). Anti-CCP antibodies were 
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measured via enzyme-linked immunosorbent assay (ELISA), 
and a result was considered positive if the level was above a 
cutoff of five arbitrary units (as suggested by Abbott 
ARCHITECT i1000SR).
 Ultrasonographic assessment Hand, wrist, elbow, 
shoulder, knee joints were evaluated via GSUS and PDUS. 
Fourteen joint regions (thus, 28 in both extremities) were 
evaluated. These included the first through to the fifth 
metacarpophalangeal (MCP), first through to the fifth 
proximal interphalangeal (PIP), the radiocarpal, ulnocarpal, 
and intercarpal compartments of the wrist; the humeroradial 
and humeroulnar compartments of the elbow; the posterior 
joint region of shoulder, the suprapatellar and medial and 
lateral parapatellar recesses of the knee joints.
 The MCP and PIP joints were scanned at palmar/plantar 
and dorsal sites; wrist joints were scanned at dorsal sites. 
All of the patients were examined by a trained 
ultrasonographer with 4 years of experience. US 
examinations were repeated at each visit (baseline, 1, 3, 6, 9, 
12, 18 months). The settings for the GSUS and PDUS were 
the same for all patients. US examinations were completed 
in 30 min, and all of the images were stored. A US platform 
featuring a 5–13-MHz linear array transducer was employed 
to this end (LOGIQ P5; General Electric, New York, NY).
 Synovitis was classified on gray-scale images using a 
semiquantitative scoring method. We considered only 
synovial proliferation as a sign of synovitis (not synovial 
effusion). The approach features use of a 0–3 scale, in which 
0 corresponds to no synovitis, 1 to mild synovitis, 2 to 
moderate synovitis, and 3 to severe synovitis. Grade 1 
synovitis may occur in normal populations, and for this 
reason, patients of grades 2 and 3 (only) were considered to 
have abnormal synovitis (12) Semiquantitative scoring 
method was evaluated for each of 28 joints, and total 
synovial scores were calculated by summing grade 2 and 3 
synovitis. The range of total GSUS synovitis score was 0–84. 
Also, GSUS synovitis score was calculated for each joint.
 The maximal area of augmentation on PDUS was 
recorded using a previously described semiquantitative 
technique featuring use of a 0–3 scale, in which 0 corresponds 
to normal/ minimal vascularity, 1 to mild hyperemia (single 
vessel signal), 2 to moderate hyperemia (confluent vessels), 
and 3 to marked hyperemia (vessel signals in >50 % of the 
joint area) (13).
 Semiquantitative scoring method was evaluated for 
each of 28 joints, and total synovial scores were calculated 
by summing each semiquantitative grade. The range of total 
PDUS synovitis score was 0–84. Figure 1 shows PDUS and 
GSUS synovitis at wrist joints.
 Tenosynovitis was recorded in the extensor digitorum 
carpi, the extensor carpi ulnaris, in each of the five flexor 
digitorum tendons of the hand, (thus a total of 14 tendons in 
both extremities). A four-grade semiquantitative scoring 
system (i.e., grade 0, normal; grade 1, minimal; grade 2, 
moderate; grade 3, severe) was used to score tenosynovitis 
revealed on GSUS. Semiquantitative scoring method was 
evaluated for each of 14 tendon regions, and total 
tenosynovitis scores were calculated by summing each 
semiquantitative grade. The range of total GSUS 
tenosynovitis score was 0–42. Figure 2 shows PDUS 
tenosynovitis at finger joints with longitudinal and 
transverse images.
 A four-grade semiquantitative scoring system (i.e., grade 
0, no Doppler signal; grade 1, minimal signal; grade 2, 
Figure 1: PDUS and GSUS synovitis at wrist joints
Bakırköy Tıp Dergisi, Cilt 14, Sayı 2, 2018 / Medical Journal of Bakırköy, Volume 14, Number 2, 2018
158
moderate signal; grade 3, severe signal) was used to score 
pathological peritendinous PD signals within the synovial 
sheath (14). Semiquantitative scoring method was evaluated 
for each of 14 tendon regions, and total PD tenosynovitis 
scores were calculated by summing each semiquantitative 
grade. The range of total PDUS tenosynovitis score was 
0–42. 
 Radiographic Assessment
 Posteroanterior radiographs of the patients’ wrists were 
obtained at baseline and at the 18. month follow-up. The 
radiographs were read by an independent radiologist, who 
was blinded regarding the clinical, laboratory, and PDUS 
findings. Radiologic damage was assessed according to the 
van der Heijde modified Sharp method for only hands (15). 
This method measures erosions and joint space narrowing 
in 32 different joints. Maximal total erosion score of the 
hands is thus 160. Maximal total narrowing score in the 
hands is 120. For only hands, the van der Heijde modified 
Sharp score is 280.
 Radiographic progression scores were defined as the 
difference between modified Sharp score at baseline and at 
18th. months. 
 Statistical Analysis
 The SPSS software (IBM SPSS statistics version 20.0) 
was used in statistical analysis. Quantitative variables 
(clinical, laboratory, and US parameters) are given as means 
with standard deviations (SD) and ranges. Upon univariate 
analysis, the Mann-Whitney U test was used to compare 
continuous variables and the chi-square test to compare 
categorical variables. Spearman’s correlation coefficients 
between radiographic and US findings were calculated. To 
determine independent predictors of radiographic 
progression scores independence of variables was 
determined by entering any significant variables from the 
univariate analysis into multiple linear regression analysis. 
AP value less than 0.05 was considered to indicate statistical 
significance. 
 RESULTS
 Baseline Clinical and Laboratory Findings 
 We included 48 early RA patients aged 18–68 years into 
the study. Among the 48 included patients, all had an 18th 
month visit, but 2 patients had no visit at 12th months.  The 
principal demographic and clinical features were 
summarized in Table 1. In total, 68% were RF-positive and 
75% were anti-CCP positive. The average ESR and CRP 
values for all of the patients were 44.04 mm/h and 24.84 
mg/dL at baseline, respectively. (ESR 0–20 mm/h, CRP 0–5 
mg/dL, normal range).
 Of a total of 1344 examined joint regions, 22.3% (n=300) 
of all examined joints had tender joints and 15.9% (n=215) 
had swollen joints. On clinical examination, tenderness was 
predominantly observed in the wrist, MCP2, and MCP3 joints 
(30.2, 21.3, and 13.5%, respectively); swelling was 
predominantly observed in the wrist, MCP2, and MCP3 joints 
(26.5, 16.5, and 13.5%, respectively).
 At inclusion, all patients were administered methotrexate 
(10–15 mg/week) and low-dose prednisone or 
methylprednisolone. After the 18-month follow-up, 23 
Figure 2: tenosynovitis at finger joints with longitudinal and transverse images
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(48.0%) patients were taking one DMARD and 25 (52.0%) 
were taking two or more synthetic DMARDs. Six patients 
(12.5%) had started therapy with adalimumab, and 2 (4.1%) 
had started therapy with etanercept. Two of the patients 
who started tumor necrosis factor (TNF) blocker therapy 
were very early RA. One patient had pulmonary rheumatoid 
nodül at 18th month follow-up.
 According to the DAS28 score, 12.5% (n=6) of patients 
exhibited low-level disease activity, 66.6% (n=32) exhibited 
moderate disease activity, and 20.9% (n=10) exhibited 
highlevel disease activity at baseline. According to the 
DAS28 score, 47.9% (n=23) of patients were in remission 
(DAS28 <2.6), 47.9% (n=23) exhibited low-level disease 
activity, and 4.2% (n=2) exhibited moderate disease activity 
at the 18- month follow-up.
 Baseline Ultrasonography Findings
 A total of 1344 joints were examined by US in all of the 
RA patients. Of these joints, GSUS synovitis was detected in 
26.4% (n=356) of joints and PDUS synovitis was detected in 
24.1% (n=325) of joints. GSUS synovitis was predominantly 
observed in the wrist, MCP2, and MCP3 joints (25.6, 18.2, and 
12.5%, respectively); PDUS synovitis was predominantly 
observed in the wrist, MCP2, and MCP3 joints (21.5, 15.5, and 
10.3%, respectively).
 A total of 672 tendons from all of the RA patients were 
examined by US. Of these tendons, GSUS tenosynovitis was 
detected in 12.6% (n=85) of tendons and PDUS tenosynovitis 
was detected in 8.9% (n=60) of tendons. The extensor carpi 
ulnaris, second flexor digitorum were the most common 
affected tendons in GSUS and PDUS (24.0, 13.5%, 
respectively).
 Baseline and Follow up Radiographic Findings
 Baseline and 18th month radiographs were available for 
44 patients. The total mean (±standard deviation [SD]) 
modified Sharp score was 11.62±4.90 at baseline in early RA 
patients. The total mean (±standard deviation [SD]) modified 
Sharp score was 8.26±3.76 at baseline in very early RA 
patients. There was statistically significant difference 
between very early RA and early RA group about radiographic 
score at baseline (p=0.001).
 Laboratory, Ultrasonographic, and Radiographic
 Course
 In the laboratory, ultrasonographic monitoring of the 
early RA patients, the parameters which improved 
statistically the earliest were the ESR and CRP levels. The 
improvement in the ESR and CRP levels is observed in the 
1st month of the treatment (p=0.007). The statistically 
significant improvement in the HAQ, DAS 28 scores, total 
GSUS synovitis score, total PDUS tenosynovitis score, total 
GSUS tenosynovitis score, and total PDUS tenosynovitis 
score begins only in the 3rd month (p=0.007, p=0.003, 
p=0.001, p=0.009, respectively). In the VAS evaluation of the 
patients, while a statistically significant difference was not 
observed when compared to the previous control, a 
statistically significant difference was found between 
baseline and 18th month of the treatment (p=0.001) (Table 
2).
Table 1. Clinical characteristics of 48 study patients with rheumatoid arthritis
Early RA (n=48) Very early RA (n=15) p values
Age, mean±SD (years) 55.56±15.54 57.00±20.45 0.063
Sex (% women) 68.7 60 0.383
BMI, mean±SD (kg/cm2) 27.39±3.11 25.17±3.81 0.075
Time elapsed from first clinical symptoms, mean±SD (months) 3.12±1.33 2.45±0.31 0.752
DAS28 scores at baseline, mean±SD 4.37±0.64 4.27±0.63 0.824
Swollen joint counts at baseline, mean±SD 3.69±2.31 2.87±1.76 0.083
Tender joint counts at baseline, mean±SD 5.65±2.65 5.20±2.88 0.752
HAQ total scores at baseline, mean±SD 39.67±12.70 34.87±13.53 0.074
Receiving synthetic DMARD monotherapy after 18 months (% patients) 48.0 46.6 0.376
Receiving two or more synthetic DMARD therapy after 18 months (% patients) 52.0 53.4 0.798
Receiving biologic DMARDs during after 18 months (% patients) 16.6 13.3 0.041
*BMI: body mass index, DAS28: Disease activity score -28, DMARD: disease-modifying anti-rheumatic drugs, HAQ: Health assessment questionnaire, SD: standard deviation.
**p values versus early RA and very early RA
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 The laboratory, US monitoring of very early RA patients, 
is similar to early RA patients. However, different from the 
early RA group, a statically significant found in the HAQ 
scores of the very early RA group, even in the 18th month 
(Table 3).
 The total mean (±standard deviation [SD]) modified 
Sharp scores increased from 11.62±4.90 at baseline to 
26.35±8.43 at 18th. months in early RA patients. The total 
mean (±standard deviation [SD]) modified Sharp scores 
increased from 8.26±3.76 at baseline to 23.27±7.58 at 18th.
months in very early RA patients. A statistically significant 
difference was seen in modified Sharp scores between 0-18 
months in early and very early RA patients (p=0.002, 
p=0.001). There was not a statistically significant difference 
between early and very early RA patients about radiographic 
scores at 18th. months and radiographic progression scores 
(p=0.071, p=0.885).
 Correlation Between Radiography or US and Clinical
 Variables
 Diagnosis duration, age, BMI did not correlate with 
radiographic progression scores in the RA patients (p>0.05). 
 Significant correlations were found between ESR, CRP 
values at baseline, ESR values at 1st month and 3rd months 
visit and radiographic progression scores (respectively, 
r=0.402, p=0.005; r=0.370, p=0.01; r=0.306, p=0.039, r=0.303, 
p=0.036). There were no correlations between RF, Anti-CCP 
positivity and radiographic progression scores (p>0.05). 
 Significant correlation was found between DAS28 scores 
at baseline, 1st month, 3rd months and radiographic 
progression scores (respectively, r=0.388, p=0.006; r=0.438, 
p=0.002; r=0.500, p=0.001). DAS 28 scores at other visits did 
not correlate with radiographic progression scores (p>0.05). 
 There were positive and significant correlations between 
total GSUS synovitis scores at baseline, 1st month, 3rd 
Table 2. Clinical, laboratory and ultrasonographic course in patients with very early rheumatoid arthritis (n=15)
Parameter Baseline 1.month 3.months 6 months 9 months 12 months 18 months
Pain, 0–10-mm VAS 4.07±2.70 4,13±0.99 4.00±1.13 3.40±0.72 2.80±0.86 2.40±0.50 1.87±0.64
ESR (mm/h) 47.47±20.45 29.54±21.45** 20.93±19.44* 14.00±8.87* 13.23±9.13 12.08±8.77 8.79±4.26
CRP (mg/dL) 24.84±26.98 12.31±9.97** 4.87±6.10* 6.54±8.89 6.00±4.04 4.77±2.35 3.64±3.64
DAS28 score 4.27±0.62 3.95±0.40 3.56±0.34* 3.21±0.39 2.93±0.30 2.78±0.39 2.69±0.31
HAQ score 34.87±13.52 32.65±12.12 24.01±10.52** 17.33±13.57** 20.13±6.76 22.00±7.29 14.00±5.18* 
Total GSUS synovitis score 4.73±2.91 4.57±3.18 2.71±2.33** 2.36±1.90 1.92±1.55 0.50±1.09* 0.64±1.08
Total PDUS synovitis score 4.40±2.82 3.86±2.65 1.36±1.90** 0.43±1.08* 0.43±1.08 0.29±0.75 0.36±0.74
Total GSUS tenosynovitis score 1.40±1.45 1.36±1.49 0.64±1.44 ** 0.57±1.45 0.42±1.05 0.29±0.72 0.33±0.65
Total PDUS tenosynovitis score 1.40±1.45 1.21±1.57 0.29±0.72** 0.00±0.00* 0.00±0.00 0.00±0.00 0.00±0.00
CRP C-reactive protein, DAS28 28-joint disease activity score, ESR erythrocyte sedimentation rate, GSUS gray-scale ultrasonography, HAQ. Health assessment questionnairre, 
PDUS power Doppler ultrasound,  VAS visual analog scale, *p<0.05 versus the preceding visit, by pairwise comparison; **p<0.01 versus the preceding visit, by pairwise comparison; 
***p<0.001 versus the preceding visit, by pairwise comparison
Table 3. Clinical, laboratory and ultrasonographic course in patients with early rheumatoid arthritis (n=48)
Parameter Baseline 1.month 3.months 6 months 9 months 12 months 18months
Pain, 0–10-mm VAS 6.34±2.40 5.54±1.22 4.21±1.20 3.67±0.93 2.90±1.18 2.44±0.76 2.25±0.97
ESR (mm/h) 44.04±25.89 25.39±15.13** 18.42±13.46* 14.50±8.10  13.13±7.58 11.65±7.26 10.06±8.16
CRP (mg/dL) 29.62±28.75 13.50±12.50** 8.69±7.83 8.96±13.58  7.13±11.29 4.15±1.92 3.47±2.71
DAS28 score 4.37±0.64 4.01±0.51 3.55±0.47* 3.05±0.49*  2.81±0.43 2.69±0.37 2.63±0.35 
HAQ score 39.67±12.70 37.54±10.43 27.58±9.12 ** 21.58±10.24*  19.76±5.76 17.71±6.84 14.21±5.23
Total GSUS synovitis score 4.60±2.28 4.54±2.33 2.91±2.40 ** 1.61±1.52*  1.09±1.23 0.48± 0.86 0.59±0.90
Total PDUS synovitis score 3.71±2.24 3.33±2.20 1.20±1.70 *** 0.35±0.84*  0.24±0.67  0.15±0.47 0.22±0.55
Total GSUS tenosynovitis score 1.88±2.48 1.80±2.52 0.70±1.65** 0.57±1.66  0.39±1.14 0.22±0.62 0.26±0.64
Total PDUS tenosynovitis score 1.56±2.27 1.24±2.32 0.52±1.53** 0.13±0.49*  0.07±0.25  0.00±0.00 0.11±0.06
CRP C-reactive protein, DAS28 28-joint disease activity score,  ESR erythrocyte sedimentation rate, GSUS gray-scale ultrasonography, HAQ. Health assessment questionnairre, 
PDUS power Doppler ultrasound,  VAS visual analog scale, *p<0.05 versus the preceding visit, by pairwise comparison; **p<0.01 versus the preceding visit, by pairwise comparison; 
***p<0.001 versus the preceding visit, by pairwise comparison
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months, total PDUS synovitis scores at baseline, 1. month, 3. 
months visits and radiographic progresion scores 
(respectively, r=0.515, p=0.001; r=0.508, p=0.001, r=0.431, 
p=0.01; r=0.503, p=0.001; r=0.501, p=0.001, r=0.411, p=0.007). 
Other US parameters did not correlate with radiographic 
progression scores (p>0.05).
 To establish an optimal model identifying variables 
influencing radiographic progression scores, we performed 
multipl lineer regression analysis on variables associated 
with p values of ≤0.2 upon univariate analysis (Spearman’s 
correlations). The dependent variable was the radiographic 
progression scores, and the independent variables were 
ESR, CRP values at baseline, ESR values at 1st month and 3rd 
months visit, DAS28 scores at baseline, 1st month, 3rd months, 
total GSUS synovitis scores at baseline, 1st month, 3rd 
months, total PDUS synovitis scores at baseline, 1st month, 
3rd months visits.
 In the multiple linear regression model, only total GSUS 
synovitis scores, total PDUS synovitis scores at baseline and 
1st month continued to show an effect on the radiographic 
progression scores in the early RA patients. Associations 
between other parameters and radiographic progression 
scores was not observed in the sample in early RA patients 
(Table 4).
 DISCUSSION 
 According to the main results of our study, US observed 
synovitis is more common in patients with RA than 
tenosynovitis. When the patients are evaluated 
longitudinally, the ESR and CRP values stand out as the 
parameters which indicated the response first in the DMARD 
treatment. The ultrasonographically and clinically 
significant improvements emerge in the 3rd month follow-
ups. This state of well-being continues as long as the 
DMARD treatment continues. In the very early RA group 
which is a subgroup in the early RA, a similar improvement 
process is observed in the ultrasonographic, clinical and 
laboratory improvement parameters. A difference was not 
found in this group in the radiological damage progression 
when compared to the early RA group. Even observing an 
improvement in only the life quality in the late term in the 
very early RA group is a remarkable result. One of the 
original findings of our study, that the most important factor 
affecting the radiographic damage progression scores is 
that the total GSUS, PDUS synovitis scores obtained at 
baseline and 1st month is high.
 US brings a new perspective on the disease follow-up in 
RA and has begun to affect the clinical decisions more than 
the physical examination. Hence, there are studies which 
demonstrate that US has the permanent disease activity 
even in the RA patients with a low disease activity and who 
are in remission and it changes the treatment decisions. 
According to the study of Dale et al. (16), although clinically 
moderate disease activity, minimal US synovitis can be 
found. Our study emerged out of the need to eliminate the 
contradictions regarding when and how US affects our 
treatment decisions. One of the main purposes is to conduct 
Table 4. Multivariate analysis of the factors associated with radiographic progression scores. 
Dependent variable R2 (adjusted) Independent variables B ß p value
Radiographic progression scores 0.384 Constant 8.275 0.558
ESR at baseline -0.054 -0.236 0.611
CRP at baseline 0.216 0.154 0.502
  ESR at 1. month 0.127 0.138 0.556
ESR at 3. months 0.054 0.236 0.611
DAS28 scores at baseline 4.646 4.324 0.293
DAS28 scores at 1.month -1.190 -0.096 0.453
DAS28 scores at 3.months -4.852 -0.366 0.453
total GSUS synovitis scores at baseline 0.091 0.417 0.011
total GSUS synovitis scores at 1.month 0.518 0.549 0.028
total GSUS synovitis scores at 3.months 2.261 1.110 0.278
total PDUS synovitis scores at baseline 0.057 0.476 0.015
total PDUS synovitis scores at 1.month 0.075 0.358 0.017
total PDUS synovitis scores at 3.months 1.154 0.214 0.507
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complete follow-ups for 18 months ultrasonographically in 
the early RA cases and associate the findings with the 
radiographic final state and progression. Although there 
are many studies carried out on this subject, there is not a 
study in which such a complete US follow-up as in our study 
is carried out. In the study of Naredo et al. (17), in which 
12-month US follow-up was carried out, it was concluded 
that PDUS is a sensitive and reliable method for the 
longitudinal evaluation in the early RA patients. It was 
stated that PDUS findings could be used in the estimation of 
the disease activity and radiologic final state prognosis. In 
this study, like in our study, 28 joint evaluations were 
employed. While the 1st-month follow-up of the patients 
was not performed, ultrasonographic follow-ups were 
carried out at 3-month intervals.  A statistically significant 
relationship was reached between the increase in the GSUS 
and PDUS findings and radiological total scores. In this 
study, the advancement in the radiographic scores was not 
elaborated on.
 Damjanov et al. (8) forecasted the radiographic erosion 
in his 6-month follow-up study and arrived at the conclusion 
that the DAS scores combined with US were more successful 
than only the DAS scores. The presence of PD positive 
synovitis in another 1-year follow-up study was associated 
with a more rapid radiographic progression. This study 
which is an early arthritis study is the largest study in terms 
of the patient group with the group of 127 patients. However, 
while it is reliable in terms of the erosion results since only 
MKF and MTF joints are evaluated in US, the results are 
contradictory in terms of the clinical and functional 
parameters and correlation results (18). In another study 
which 38 patients were followed for 2 years, it was determined 
that erosion developed at the end of 2 years in the PD 
synovitis cases who has excessed values at the onset and it 
did not develop in the PD-negative patients. This study is an 
effective study since it has complete US follow-ups and 
follow-up periods (19). In the study carried out by Ikeda et al 
(20) in 2013, the late-term patients the US follow-ups of 
whom were performed in 0-12-24 months were compared 
as patient groups receiving methotrexate, anti-TNF, and 
tocilizumab treatment. It was determined that the 
radiographic erosion scores at the end of 2 years, that the 
outset PD synovitis scores were an independent risk factor 
for the erosion development in the group receiving 
methotrexate. As for the group receiving anti-TNF and 
tocilizumab treatment, it was demonstrated that the fact 
that PD synovitis scores were high did not lead to 
radiographic erosion. Different from our study, it is possible 
that the fact that the treatment was administered to the 
established patients may have caused the encounter with 
such a result. The studies in which early RA patients are 
included and in which a follow-up study can be carried out 
after the use of methotrexate, biologic agent in a naive 
fashion at the onset may give similar results to the study of 
Ikeda et al. However, performing such a study design does 
not seem possible in many countries in regards to the 
conditions of starting the biologic agent of the repayment 
institution.
 While the results of our study are parallel with the study 
of Pascual-Ramos et al. (19),  it prominently demonstrates 
that a radiologic damage develops in the patients with the 
high baseline and 1 month PDUS and GSUS total scores. 
This case is the indirect proof of how much neovascularisation 
increases the disease morbidity in RA. The importance of the 
persistence of PD synovitis on the erosion development is 
known but more importantly, the fact that the high baseline 
PD synovitis severity develops erosion even in the early RA 
patients emerges as a new finding. Thus, based on these 
results, it will not be wrong to say that the own burden of the 
disease determines the fate of the disease. Applying more 
aggressive treatment protocols apart from the standard 
treatments in patients with high PD synovitis scores at the 
onset can be offered as a recommendation.
 When the clinical and laboratory follow-ups of the early 
RA patients are examined, the most striking parameters 
which improve with the treatment are acute phase reactants 
being ESR and CRP. For the decrease in the disease activity 
and the significant increase in the daily life activities, 
although the patients are diagnosed very early, it is 
necessary to wait for the 3rd month. In parallel with the 
results of our study, the improvement in the laboratory 
findings occurs in the 1st month in the similar studies (21,22).
 The important advantage of our study, differently from 
other studies, is having included early RA patients and 
having carried out US follow-ups very completely. Having 
included the very early RA diagnosed patients as a 
subgroup in the early RA group in the follow-up is another 
advantage.
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 The fact that the interobserver and intraobserver 
reliability tests of the use of single ultrasonography were 
not carried in the US examination is one of the limitations of 
our study. Another limitation is the fact that carrying out the 
US evaluation in line with DAS 28 leads to not evaluating 
ankle and MTF joints.
 As a result, our study has shown to clinicians and US 
applicators that the similar US findings are present in the 
early RA and very early RA patients and the ultrasonographic 
response to the treatment occurs in the similar periods. 
Although the baseline radiographic damage scores are 
different, the radiographic damage progresses are similar in 
these patient groups. The most important factor affecting 
the radiographic damage progression is the severity of 
ultrasonographic synovitis at the baseline and in the 1st 
month, independently of the disease activity. The studies in 
which the follow-up periods are longer and the patient 
groups are more diverse will shed light on explaining 
different development reasons of the radiographic damage.
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